Abstract
Positron emission tomography (PET) using fluorine-18 (FDG) is increasingly used in the staging of lymphoma. Results of the use of PET during and after completion of therapy for staging of Hodgkin’s lymphoma and aggressive non-Hodgkin’s lymphoma demonstrate a highly predictive value for outcome. Based on recommendations of the International Harmonization Project, FDG-PET has been incorporated into the revised response criteria of lymphoma. There is currently no evidence to support the use of FDG-PET in indolent lymphoma, nor for its routine use during follow-up. Evidence also lacks on the impact of FDG-PET on treatment outcome. Clearly, well designed clinical trials are warranted to determine the subsets of patients that will benefit from this modality.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.